Positive outcome when S2Medicals antimicrobial peptides were tested against the multi resistant bacteria that by WHO have been defined as a global health threat

LINKÖPING, Sweden, Jan. 2, 2023 /PRNewswire/ -- Scientists from the HeAliX-project which the Company is a part of have evaluated the antimicrobial effect from the peptide technology that the Company acquired and that goes by the name "Admercin". The new results from the in vitro study show a substantially positive outcome. Several versions of Admercin have been evaluated and showed good effect against half of the bacteria and extremely good effect against the rest. All the evaluated substances could both prevent proliferation as well as kill the bacteria. The ESKAPE-bacteria consist of the frequently seen, and in many cases problematic bacteria

Enterococcus faecium, Staphylococcus aureus (MRSA), Klebsiella pneumonia, Acinetobacter baumanii, Psudomonas aeroginosa andEnterobacter cloacae. These bacteria have been selected by WHO who appeal for new antibiotics to be developed. The bacteria can according to WHO cause deadly infections since they already today have developed a resistance against the most potent antibiotics available. As previously reported, WHO has reported that antibiotic resistance remains one of the most serious threats to humanity and will surpass cancer in number of deaths and cost 100 000 billion USD annually if nothing is done. The research on antimicrobial peptides that is being reported in this press announcement is funded by external grants and is performed in collaboration with Linköping University, Örebro University and Luleå University of Technology.

"The fact that our technology is effective against these bacteria shows that the potential for the technology is huge. We are looking forward to rapidly develop products that include Admercin. We also view the benefit for humanity for these peptides as so big that we are considering to open up for other actors to license them from us" says the Company's CEO Petter Sivlér

This disclosure contains information that S2Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 02-01-2023 17:15 CET.

CONTACT:

Contact Details

Petter Sivlér - CEO, S2Medical AB (publ)

Telephone: +46 (0)8-70 000 50

E-mail: petter.sivler@s2m.se

Certified Adviser

Vator Securities AB

Telephone +46 (0)8-580 065 99

Website: www.vatorsec.se 

E-mail: ca@vatorsec.se

The following files are available for download:

https://mb.cision.com/Main/17719/3691966/1761682.pdf

Release

Cision View original content:https://www.prnewswire.co.uk/news-releases/positive-outcome-when-s2medicals-antimicrobial-peptides-were-tested-against-the-multi-resistant-bacteria-that-by-who-have-been-defined-as-a-global-health-threat-301712004.html



Veröffentlicht am 02.01.2023

Aktuelle Research Artikel

Biotechnologie

BioNxt: Neue Ära der Chemotherapie mit Kursziel 2,50 EUR

BioNxt Solutions Inc. Aktie (WKN: A3D1K3): BioNxt Solutions entwickelt gezielte Krebstherapien und sublinguale Schmelzfilme, um Nebenwirkungen zu reduzieren und Patientenkomfort zu erhöhen.
Rohstoffe

Kursziel 8,55 EUR: Warum Analysten in Rektron großes Potenzial sehen

Rektron Group Inc. Aktie (WKN: A407W8): Rektron Group Inc. ist ein agiler Rohstoffhändler, der sich auf Nachhaltigkeit und digitale Trends konzentriert und in Wachstumsmärkten wie Indien, Vietnam und Afrika expandiert.
Biotechnologie

Radiopharmazeutika: Warum diese Biotech-Aktie in Ihr Depot gehört

Defence Therapeutics Inc. Aktie (WKN: A3CN14): Defence Therapeutics entwickelt mit Accum® eine Plattform, die die intrazelluläre Wirkstofffreisetzung verbessert und in der Biotech-Branche für Krebs und Infektionskrankheiten innovativ ist.
Gütertransport

Saia Inc.: Die Aktie, die Amerikas Waren bewegt

Saia, Inc. Aktie (WKN: A0KDU8): Saia Inc. ist ein Spezialist für Less-than-Truckload-Transporte, bekannt für operative Exzellenz und Innovation, mit fast 100 Jahren Erfahrung und stetigem Wachstum.
 Ja, ich möchte den Newsletter abonnieren!*
* Sie können sich jederzeit aus dem Newsletter heraus abmelden. Weitere Informationen zum Thema Datenschutz erhalten Sie in unserer Datenschutzerklärung